Advances in Leukemia Treatment with Bone Marrow TransplantationSusumu Ikehara*
Susumu Ikehara, Department of Stem Cell Disorders, Kansai Medical University, Hirakata City, Osaka 570-1010, Japan
- *Corresponding Author:
- Susumu Ikehara
Department of Stem Cell Disorders
Kansai Medical University, Hirakata City
Osaka 570-1010, Japan
E-mail: [email protected]
Received date: February 06, 2014; Accepted date: April 25, 2014; Published date: May 10, 2014
Citation: Ikehara S (2014) Advances in Leukemia Treatment with Bone Marrow Transplantation. J Leuk (Los Angel) 2:136. doi: 10.4172/2329-6917.1000136
Copyright: © 2014 Ikehara S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Bone Marrow Transplantation (BMT) is a useful strategy for the treatment of leukemia, severe combined immune deficiency, enzyme deficiencies, autoimmune disease, and osteoporosis . Furthermore, BMT plays an important role in the induction of immune tolerance in organ transplantation. Bone marrow is a spongy tissue, and is made up of Hematopietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs), and various blood cells. HSCs differentiate into common myeloid- and lymphoid-precursor cells and then terminally differentiate into erythrocytes, monocytes, platelets, neutrophils, dendritic cells and other cells. MSCs can differentiate into not only mesoderm derived-cells such as adipocytes, osteoblasts, and osteoclasts, but also endodermand ectoderm-derived cells.